Unknown

Dataset Information

0

Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer.


ABSTRACT:

Purpose

To evaluate the tolerability of escalating doses of stereotactic body radiation therapy in the treatment of localized prostate cancer.

Patients and methods

Eligible patients included those with Gleason score 2 to 6 with prostate-specific antigen (PSA) ≤ 20, Gleason score 7 with PSA ≤ 15, ≤ T2b, prostate size ≤ 60 cm(3), and American Urological Association (AUA) score ≤ 15. Pretreatment preparation required an enema and placement of a rectal balloon. Dose-limiting toxicity (DLT) was defined as grade 3 or worse GI/genitourinary (GU) toxicity by Common Terminology Criteria of Adverse Events (version 3). Patients completed quality-of-life questionnaires at defined intervals.

Results

Groups of 15 patients received 45 Gy, 47.5 Gy, and 50 Gy in five fractions (45 total patients). The median follow-up is 30 months (range, 3 to 36 months), 18 months (range, 0 to 30 months), and 12 months (range, 3 to 18 months) for the 45 Gy, 47.5 Gy, and 50 Gy groups, respectively. For all patients, GI grade ≥ 2 and grade ≥ 3 toxicity occurred in 18% and 2%, respectively, and GU grade ≥ 2 and grade ≥ 3 toxicity occurred in 31% and 4%, respectively. Mean AUA scores increased significantly from baseline in the 47.5-Gy dose level (P = .002) as compared with the other dose levels, where mean values returned to baseline. Rectal quality-of-life scores (Expanded Prostate Cancer Index Composite) fell from baseline up to 12 months but trended back at 18 months. In all patients, PSA control is 100% by the nadir + 2 ng/mL failure definition.

Conclusion

Dose escalation to 50 Gy has been completed without DLT. A multicenter phase II trial is underway treating patients to 50 Gy in five fractions to further evaluate this experimental therapy.

SUBMITTER: Boike TP 

PROVIDER: S-EPMC3138546 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3356012 | biostudies-other
| S-EPMC4245005 | biostudies-literature
| S-EPMC7276661 | biostudies-literature
| S-EPMC6906721 | biostudies-literature
| S-EPMC5522851 | biostudies-other
| S-EPMC8772149 | biostudies-literature
| S-EPMC5654655 | biostudies-literature
| S-EPMC11262986 | biostudies-literature
| S-EPMC5002986 | biostudies-literature
| S-EPMC3986382 | biostudies-other